VJVirtual | The switch to ofatumumab after liver injury associated with ocrelizumab treatment in MS

Alice Mariottini, MD, University of Florence, Florence, Italy, discusses a case report of a woman in her 50s with multiple sclerosis (MS) who experienced liver injury following treatment with ocrelizumab. Dr Mariottini suggests that the liver injury following ocrelizumab is usually associated with a viral infection. The patient was switched to ofatumumab, which uses a different route of administration and was safe and effective. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.